GSA Capital Partners LLP Takes Position in Krystal Biotech, Inc. $KRYS

GSA Capital Partners LLP bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, HoldingsChannel reports. The firm bought 1,643 shares of the company’s stock, valued at approximately $611,000.

Other hedge funds also recently made changes to their positions in the company. USA Financial Formulas bought a new stake in Krystal Biotech during the first quarter valued at $44,000. Summit Global Investments bought a new position in Krystal Biotech in the 2nd quarter worth about $805,000. Oppenheimer Asset Management Inc. acquired a new stake in Krystal Biotech in the 2nd quarter valued at approximately $259,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Krystal Biotech during the second quarter valued at $337,000. Finally, GAMMA Investing LLC grew its position in Krystal Biotech by 16.3% in the 2nd quarter. GAMMA Investing LLC now owns 998 shares of the company’s stock valued at $371,000 after buying an additional 140 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on KRYS. Jefferies Financial Group reissued a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup increased their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada initiated coverage on Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Stock Down 1.8%

Shares of KRYS stock opened at $337.02 on Friday. The stock has a 50-day simple moving average of $346.45 and a 200 day simple moving average of $301.08. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The stock has a market capitalization of $9.98 billion, a P/E ratio of 42.23 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Insider Activity

In related news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 51,642 shares of company stock worth $16,471,923. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.